News Stories

On January 29, the U.S. FDA approved mipomersen sodium injection as an adjunct to treat LDL-C, Apo B, total cholesterol, and non HDL-C in patients with homozygous familial hypercholesterolemia (HoFH). Mipomersen, known by the brand name Kynamro, will be marketed in the U.S. by Genzyme, a Sanofi company. The mipomersen clearance follows a 9-6 vote in favor of the drug's approval by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee this past October.

A comprehensive new review on how to treat high cholesterol and other blood lipid problems suggests that intensive treatment with high doses of statin drugs is usually the best approach.

Ideas, Inventions And Innovations Blog - October 15, 2012

Following an October 2012 recommendation by the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved lomitapide for patients with homozygous FH. Lomitapide, known by the brand name Juxtapid, is produced by Aegerion Pharmaceuticals.